The market for prophylactic cancer vaccines is sizable, bigger in fact than the market for any type of cancer therapeutic.  Afterall, doctors administer cancer drugs only after a patient has been diagnosed, while a vaccine can be administered to a far wider population.

In the U.S., 268,000 women are expected to be diagnosed with breast cancer this year.  At this moment, however, 50 million women are over the age of 40 – the time in life when women face an increased risk of developing breast cancer.  And every year, several million additional women will age into this population bubble.  Worldwide, the number is exponentially larger.